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Background: From an epidemiological perspective, the practice of universal vaccination of girls and young women
in order to prevent human papilloma virus (HPV) infection and potential development of cervical cancer is widely
accepted even though it may lead to the neglect of other preventive strategies against cervical cancer.
Discussion: It is argued that removing the deterrent effect – the fear of developing cancer – could encourage
teenage sex. This paper reflects on the ethical legitimacy of the universal vaccination of girls and young women
against HPV infection, especially regarding safety issues, the need to vaccinate people who have opted to abstain
from sex, the presumption of early onset of sexual relations, the commercial interests of the companies that
manufacture the vaccine, and the recommendation of universal vaccination in males.
Summary: Based on the aforementioned information, we believe that the universal vaccination against HPV in
young women is acceptable from an ethical point of view, given the medical advantages it presents.
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Human papilloma virus (HPV) is routinely found in
humans. There are more than 100 different types of HPV,
but not all are health threatening. Some cause common
condylomas and others plantar warts, but there is a group
of HPVs that mainly infects the mucous epithelium of the
anogenital tract and has an oncogenic nature [1].
Around 40 types of HPV are transmitted primarily
through sex, causing a mucous infection, especially in
the anogenital region [1]. Condoms do not appear to be
an effective solution to prevent their transmission [2-8].
In the reproductive stage of its life cycle, HPV multi-
plies inside the infected cell, causing cell alterations that
lead to morphological changes in the epithelial tissue
and other types of lesions [9].
Genital infections due to HPV are very common. Most
occur in young women although 70% disappear spontan-
eously within one year and 90% within two years [10].
When this type of infection does not remit spontaneously
and persists over time, it can become a precursor of high-
grade lesions [9,10] which can subsequently develop into* Correspondence: justo.aznar@ucv.es
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distribution, and reproduction in any mediumcancerous lesions; it has even been stated that HPV infec-
tion is necessary for the development of cervical cancer in
around 98% of cases [11,12].
Of the more than 100 different variants of HPV, [13]
types 16 and 18 cause more than 70% of cervical cancers
in Europe [14]. Furthermore, cervical cancer is the sec-
ond most common cancer in women worldwide, after
breast cancer [15,16]. In addition, HPV infection is also
responsible for other types of cancer in women, such as
vaginal and vulvar cancer, and also for certain cancers in
males, such as oropharyngeal, penile, and anal canal can-
cer; [3,11]. HPV infection is present in more than 85%
of cases of the latter [17].
Incidence
Worldwide, HPV infection is responsible for more than
half a million cases of cancer and more than 250,000
deaths every year [15,16]. The highest incidence occurs in
developing countries, mainly due to a lack of resources in
secondary prevention and treatment of the disease, and
poor sex education of the population [15,16,18,19]. HPV
infection is not yet a major problem in Spain, which to
date has one of the lowest cervical cancer rates in the
world [20,21] with mortality rates below 2.2/100,000
women/year, and fewer than 1000 deaths annually [22].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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The most effective measure for preventing cervical cancer
in the last century was the introduction of cervical screen-
ing programmes, especially the Papanicolaou test, for the
early detection of precancerous lesions in women that
were already infected (secondary prevention). This test
has high specificity, but low sensitivity and so erroneous
results are not uncommon [23]. Furthermore, not all
women worldwide have had access to the test – especially
in developing countries, but also in developed countries –
so it has not been effective at a global level. There are cur-
rently other secondary prevention strategies, such as the
HPV determination test [24] which is a more sensitive
technique than the Papanicolaou test and causes fewer in-
correct results. However, its generalised implementation
in industrialised countries is in its early stages.
Even though an intervention on the modifiable risk fac-
tors (i.e. oral contraception, [25] smoking, [26] age of first
sexual intercourse, promiscuity, [27] or other infections,
[28] etc.) would be the most effective action to prevent in-
fection, it has not had a major impact on the elevated inci-
dence of infection and cervical cancer so far. For this
reason, it has been necessary to develop alternatives to
complement screening programmes [29,30]. In this re-
spect, universal HPV vaccination has been proposed fol-
lowing the success of vaccination for the prevention of
other types of infections [31].
HPV vaccination
In 2006, the WHO recognised the high efficacy (99.8%) of
the HPV vaccine in preventing moderate and severe pre-
cancerous cervical lesions associated with HPV types 16
and 18 in women not previously infected by these types
[32-35] as well as the safety of the anti-HPV tetravalent
vaccine [36]. Accordingly, the Food and Drug Administra-
tion (FDA) and European Medicines Agency (EMEA) ap-
proved the administration of the HPV vaccine in humans
at the end of the same year, authorising its administration
to girls from the age of 9 years. Its use was recommended
at this early age (between 9 and 14 years) due to its greater
immunogenicity with respect to later ages, and to obtain
protection before the first sexual relations [37-40].
Some problems that may occur due to the universal use
of the HPV vaccine
For the reasons previously stated, it appears that, from a
medical and sociological point of view, recommending
universal vaccination of women, especially girls and
young women, is an appropriate health measure, and it
was introduced into vaccination schedules following
pharmaco-economic and opportunity analyses. However,
recommending the universal vaccination of girls and
young women may entail ethical problems that may make
it difficult to implement these campaigns. Assessing theseethical considerations will constitute the main part of our
paper.
Discussion
Ethical considerations with respect to the infection and
its vaccine
Some of the potential ethical issues that HPV vaccin-
ation may give rise to are as follows:
Possible existence of negative side effects
The side effects reported after administration of the vaccine
have been mainly local reactions, while signs or symptoms
of greater importance have been reported in very rare cases
[33,39,41]. Since the FDA and the EMEA approved the vac-
cine in 2006, more than 120,000,000 people worldwide have
been vaccinated, and there have been no known deaths due
to the vaccine preparation [42].
Furthermore, taking into account that the vaccine has
an efficacy of practically 100% for preventing precancer-
ous lesions caused by the viral genotypes included in the
vaccine [32-35] and that the adverse events reported did
not endanger the health of the adolescents, these side ef-
fects cannot be a sufficient contraindication for universal
vaccination as the vaccine's benefits far outweigh any
possible harm. Even in the case in which a woman has
already had contact with one type of HPV and thinks
that the benefits provided by the vaccine may not offset
the adverse effects, the vaccine may protect her against
the genital disease caused by other types of viruses in-
cluded in the preparation and so its administration is
still indicated.
Whether or not to vaccinate people who have opted to
abstain from sex
Adolescents who have decided to maintain sexual abstin-
ence, either due to education or personal choice would
not technically be susceptible to HPV infection, as they
are not exposed to at-risk relationships, so it would not be
necessary to vaccinate them. However, absolute sexual ab-
stinence is not an easy option to maintain and can vary
throughout life, especially if we take into account that the
age at which the vaccination is recommended is between
9 and 14 years old, an age at which it is unlikely that girls
will have adopted a sexual behaviour that will remain un-
altered throughout their life.
Furthermore, even if they remain true to that deci-
sion, this is unlikely to be maintained after marriage.
Even though sexual intercourse takes place within the
couple itself and is based on the fidelity and exclusivity
of the spouses, it may be that one or both spouses has not
maintained an attitude of sexual abstinence during their
entire premarital life and so there may be the possibility
that one of them is infected with HPV and could infect
the healthy partner. In order to prevent this hypothetical
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spouse was infected with HPV before the marriage, but this
practice seems difficult to accomplish socially. Vaccination
prior to marriage could be recommended, although, as has
been mentioned, the effectiveness of the vaccine is highest
if administered between the ages of 9 and 14 years because,
at that age, a higher antibody titre is generated than at later
ages [43]. It appears, therefore, that the time prior to mar-
riage is not ideal for administering the vaccine. Conse-
quently, not only does it appear advisable to vaccinate but
it should also be done in the most effective age range.
Presumption of early onset of sexual relations for
recommending the vaccination
The recommendation for the universal HPV vaccin-
ation of girls and young women is based, on the one
hand, on the possible early onset of sexual relations,
[44] and, on the other, because studies on the vaccine's
effectiveness in relation to the age at vaccination have
shown that the effectiveness is lower when the vaccine
is given after the age of 9–14 years [38]. In both cir-
cumstances, the universal vaccination of girls and
young women appears justified [32,33,45]. However,
given that from any point of view it is considered ad-
visable to delay the age of onset of sexual relations, the
recommendation for universal vaccination should be
accompanied by educational campaigns that recom-
mend delaying sexual relations, and should also pro-
mote awareness of the serious medical consequences
of HPV infection [46] and other risky behaviours.
Be that as it may, sometimes universal HPV vaccin-
ation may be part of a family or public strategy that
seeks to facilitate the onset of sexual relations in young
people, sparing them greater risks, especially the danger
of developing cervical cancer. In relation to this, even if
vaccination were part of that strategy, the vaccination in
itself would not be unethical; it is the strategy that
would be unethical, i.e. the ethical problem would have
to be shifted to the strategy that forms the context of
the vaccination and not the vaccination itself, because
obviously the instrumentalisation (using something that
is not your own for a purpose) of vaccination pro-
grammes does have an ethical content, or because it de-
liberately encourages a good thing to mislead and
promote something bad (“safe sex”), or because it pre-
vents a good thing so that it cannot be exploited for
something bad (“safe sex”). Both choices are unethical
and are not justified by the possible good intention.
How the interests of the commercial firms that manufacture
the vaccine could affect its use
When making an ethical reflection on the advisability
of a universal vaccination policy for girls and young
women, the interests of the commercial firms thatmanufacture the vaccines, as well as the intermediary
agents, and to what extent the economic benefits for
both could influence decision-making should be taken
fully into account. In fact, it is essential that, in order
to ensure the correct choice of vaccine and the pro-
grammes to be implemented, the administration gives
priority to the economic efficiency of the potential vac-
cines to be used – this would guarantee the suitability
of the vaccination programmes chosen.
It should also be taken into account that the research
processes required to develop viable vaccines are very
costly. At present, the main economic investment for
the development of new vaccines is made by the com-
mercial firms and so, in order to maintain the in-
vestment, the vaccines obtained must be marketed
effectively. It is obvious that if they do not achieve high
use of the vaccines, they cannot continue investing in
research. The information on HPV infection given to
the general public should be improved, which is why
many companies carry out information campaigns on
HPV and its vaccine together with their vaccination
campaigns [47]. Information campaigns on HPV are an
effective way to improve the vaccination effectiveness.
If the vaccine is not sold, users will not be able to
benefit from the advances of medical research compan-
ies. For this reason, it is important to determine which
vaccines are useful for the population and to use them
in vaccination programmes to provide feedback to the
scientific-economic process and, in this way, to be able
to continue to gain improvements and medical break-
throughs in the future.
Advisability of proposing universal vaccination in males
The massive vaccination of males might be one measure
that could reinforce the results of vaccine protection
[45,48]. Although males do not have a risk of cervical
cancer, they form part of the epidemiological chain of
infection because they are essential elements in virus
transmission between people. For this reason, collective
immunity may be fundamental in the infection of women
and its subsequent consequences.
Moreover, previous studies have assessed the in-
clusion of males in the vaccination programmes and
have found a cost-benefit relationship that is suffi-
cient to opt for inclusion, [49,50] although the set-
ting in which these studies were conducted was, and
is, changing. It is obvious that there is a different
setting in each region and so new evaluations in dif-
ferent areas could modify any decisions taken in the
future. Furthermore, there are other cancers asso-
ciated with chronic HPV infection that do directly
affect men, such as cancers localised in the penis,
anus or oropharynx, which is why the vaccination of
men must continue to be evaluated.
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universal vaccination of girls and young women
General aspects
When making an ethical assessment on whether to pro-
mote universal campaigns in favour of the vaccination of
girls and young women with the HPV vaccine, in our
opinion, the first question that arises is whether it can
be considered ethical to remove the deterrent effect that
is the fear of acquiring a serious and, in fact, fatal illness,
as a result of the universal use of the HPV vaccine, and
whether the disappearance of this deterrent effect could
promote sexual relations among adolescents and young
people. In relation to this, we believe that the first ques-
tion that should be asked is: “Is it ethically acceptable to
base the proper use of human sexuality on the fear of
contracting a serious disease (consequently discouraging
the use of a medical action, which in itself does not en-
tail any direct ethical difficulty) because of the possibility
that said medical action might reduce the hypothetical
fear of developing the disease, which could indirectly
contribute to encouraging sexual relations in young
people when the deterrent effect represented by the pos-
sibility of infection and development of this disease dis-
appears?” In other words: “Can we stop using a useful
medical measure to prevent a disease – a measure that
in itself does not have any ethical difficulty – amid fears
that it could indirectly encourage sexual promiscuity in
young people?” This is a question that, specifically in re-
lation to the HPV vaccine, could be asked as follows: “Is
it ethically acceptable not to promote universal HPV
vaccination in girls and young women for fear that this
could reduce the deterrent effect – i.e. the fear of devel-
oping cervical cancer – and that this could encourage
sexual relations in young people?”
Introductory moral reflexion
Human sexuality is far from being solely a physiological
mechanism for reproduction, undoubtedly an extremely
important end in itself, but it is also an expression of phys-
ical and spiritual love between a man and a woman. It is
not only an instrument to generate pleasure, but is also an
expression of human love, hence its greatness, which goes
well beyond a mere reproductive mechanism.
Due to the physical and spiritual nature of sexuality, it
follows that its exercise cannot be evaluated exclusively
from a biological aspect, but should also be assessed
from an ethical point of view. To that end, the ethical
aspect of the exercise of human sexuality forces us to
consider this when evaluating actions that affect it in
some way – this is true in the case of the HPV vaccine.
Therefore, any action or act related to human sexuality
requires an ethical evaluation.
We are of the opinion that the ethical evaluation on
the use of the HPV vaccine, in principle, could be classifiedwithin the so-called “double effect” actions. “Double effect”
actions are those that simultaneously cause two effects, one
of which is morally positive and the other negative.
Traditionally, it has been postulated [51] that to assess
the moral lawfulness of a “double effect” action, four con-
ditions are required: a) that the action in itself be positive
or at least indifferent; b) that the negative secondary effect
may not be the cause or the means to achieve the positive
primary effect; c) that there is no other valid alternative;
d) that there be a certain proportionally grave reason be-
tween the positive and the negative effect. However, a
more specific interpretation of the “double effect” moral
principle has recently been proposed, reducing it to
whether there is a “proportionate reason” for carrying out
the direct action [52]. Thus, in the first place, we have to
assess whether the specific action of universal HPV vac-
cination can be effectively treated using the moral figure
of “double effect” actions.
In our opinion, we believe that the vaccination cannot be
classified within the moral judgement merited by “double
effect” actions, since the effect sought – i.e. to prevent an
infection that may cause a serious or even fatal disease,
something that can be achieved with the vaccination – is
not accompanied by any negative side effects that could
morally invalidate the positive primary effect sought. How-
ever, in certain circles, it is argued that proposing universal
HPV vaccination, especially in adolescents, could encour-
age sexual relations between adolescents by removing the
deterrent effect of the fear of contracting a serious disease,
something that, in our opinion, cannot be directly inferred
from the very fact of the vaccination, especially if we take
into account that by proposing the vaccination at early
ages, this is removed in time from the possible onset of
sexual relations, and so conflating vaccination and sexual
activity does not appear to be justified.
Furthermore, a recent study conducted in the United
States [53] assessed the sexual activity of a group of girls
who had been vaccinated against HPV, comparing it
with another group with similar characteristics who had
not received it. According to the authors, “HPV vaccin-
ation in the recommended ages was not associated with
increased sexual activity-related outcome rates”.
Likewise, there is an added circumstance that we be-
lieve may invalidate the negative ethical judgement that
vaccination might merit when considering, as already in-
dicated, that it could promote sexual promiscuity by re-
moving the deterrent effect for preventing sexual
relations between adolescents. This circumstance is that,
with the use of the HPV vaccine, development of a ser-
ious disease (cervical cancer) that is acquired sexually
can be reduced or prevented, but it does not prevent the
spread of other sexually transmitted diseases, among
them some as serious as HIV; in other words, it does
not seem that, with the potential to be able to prevent
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inate the risk of spread of other sexually transmitted
infections, we can continue using the argument that by
removing the deterrent effect, which is reducing the
risk of developing cervical cancer, by eliminating a sin-
gle possibility of infection, one might think that we are
going to contribute to an increase in sexual relations
among adolescents, if the risk of contracting other
equally serious sexually transmitted diseases through
these relations remains.
In addition to this, and with respect to infection with
HIV and other sexually transmitted diseases, it could
be argued that together with vaccination, it could pro-
mote the use of condoms and so would achieve so-
called “safe sex”, i.e. adolescents could have sexual re-
lations without the possibility of being infected, espe-
cially with HIV. However, this seems misleading, since
it is well known that using condoms does not com-
pletely prevent the possibility of being infected with
the virus in a heterologous couple, i.e. with one healthy
partner and the other HIV-positive, as using a condom
for this purpose has a failure rate of between 5% and
10% [54-60].Inalienable right of parents to decide whether or not to
vaccinate their daughters
One aspect that – regardless of the advisability or not of
the universal vaccination of girls and young women – must
be left quite certain, is the inalienable right of parents to de-
cide about the sex education of their children, and, there-
fore, the parents must be provided with all the information
relative to the use of the HPV vaccine and the conse-
quences that it could have in relation to their sexual activ-
ity. It is particularly important that parents, in the context
of a universal vaccination programme for adolescents, can
refuse to have their daughters vaccinated if they consider it
appropriate – a right that should be made explicit in the
vaccination campaign. In order to ensure this parental au-
tonomy, even if the vaccine is promoted or recommended
by the public health authorities, the final decision on its use
should always remain in their hands [61-63].Summary
In summary, we believe that proposing a universal HPV
vaccination campaign in girls and young women does not
entail any particular ethical difficulties, providing that the
aforementioned premises are taken into account, so we do
not see any major drawbacks in proposing it.
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